N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(propan-2-yl)benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-5-methylpyrazine-2-carboxamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]pyridine-2-carboxamide;

4-tert-butyl-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzenesulfonamide;

2,4-dichloro-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzenesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]naphthalene-2-sulfonamide;

5-[2-(2,4-difluorophenoxy)-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one; and

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-N-methyl-1-phenylmethanesulfonamide.

In another aspect, the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound as described above, or a pharmaceutically acceptable acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

In another aspect, the present disclosure relates to the use of a compound as described herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating acute myelocytic leukemia, bladder cancer, breast cancer, colon cancer, glioblastoma, head and neck cancer, hepatocellular cancer, melanoma, multiple myeloma, non small cell lung cancer (NSCLC), non-Hodgkin's lymphoma (NHL), pancreatic cancer, prostate cancer, renal cell carcinoma (RCC), sarcoma.

In another aspect, the present disclosure relates to the use of a compound as described above, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating AIDS.

In another aspect, the present disclosure relates to the use of a compound as described above, or a pharmaceutically acceptable acceptable salt thereof, for use in treating obesity.

In another aspect, the present disclosure relates to the use of a compound as described above, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating type II diabetes.

In another aspect, the present disclosure relates to the use of a compound as described above, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating an acute kidney disease or condition, wherein said acute kidney disease or condition is selected from the group consisting of: ischemia-reperfusion induced kidney disease, cardiac and major surgery induced kidney disease, percutaneous coronary intervention induced kidney disease, radio-contrast agent induced kidney disease, sepsis induced kidney disease, pneumonia induced kidney disease, and drug toxicity induced kidney disease.

In another aspect, the present disclosure relates to the use of a compound as described above, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating a chronic kidney disease or condition, wherein said disease or condition is selected from the group consisting of: diabetic nephropathy, hypertensive nephropathy, HIV-associated nephropathy, glomerulonephritis, lupus nephritis, IgA nephropathy, focal segmental glomerulosclerosis, membranous glomerulonephritis, minimal change disease, polycystic kidney disease and tubular interstitial nephritis.

In another aspect, the present disclosure relates to pharmaceutical compositions comprising a pharmaceutically acceptable exicipient and a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof.

In another aspect, the present disclosure relates to methods of treating cancer in a subject comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable acceptable salt thereof, to a subject in need thereof. In certain embodiments, the cancer is selected from the group consisting of: acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia

2,5-dichloro-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(propan-2-yl)benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-5-methylpyrazine-2-carboxamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]pyridine-2-carboxamide;

4-tert-butyl-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzenesulfonamide;

2,4-dichloro-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzenesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]naphthalene-2-sulfonamide;

5-[2-(2,4-difluorophenoxy)-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one; and

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-N-methyl-1-phenylmethanesulfonamide.

2. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

3. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating acute myelocytic leukemia, bladder cancer, breast cancer, colon cancer, glioblastoma, head and neck cancer, hepatocellular cancer, melanoma, multiple myeloma, non-small cell lung cancer (NSCLC), non-Hodgkin's lymphoma (NHL), pancreatic cancer, prostate cancer, renal cell carcinoma (RCC), sarcoma.